A new approach in Alzheimer's Research
Home
About Us
Technology
Contact

SeptaTherapeutics

Septa Therapeutics Inc. is a biotechnology company devoted exclusively to the development of an effective treatment for Alzheimer’s Disease (AD).

The scientific community has looked long and hard for the "trigger" that initiates the events leading to AD and agrees that it lies somewhere in the amyloid beta protein that accumulates in the brains of AD patients. Septa Therapeutics Inc. has identified the likely trigger, using a new approach, based on the platform technology developed earlier by CEO Diane Van Alstyne, Ph.D.

Septa Therapeutics has used this technology to identify hMCP-1 chemokine activity in amyloid beta. This activity transforms stem cells from rat brain into microglia which have been shown recently to be the primary cause of neuron death.

These data are contained in:

US Patent 62/613,621, PCT/CN2019/05004 filed Jan. 4, 2018. Septapeptides representing common epitopic sites for AD associated agents. D. Van Alstyne,

and in the manuscript, posted Sept.23, 2018. doi:10:1101/424838. An Amyloid beta-derived Septapeptide has hMCP-1 activity. D. Van Alstyne.

We have also presented this data at 2 international conferences:

Keystone Symposia: Advances in Neurodegenerative Disease Research and Therapy. June 20, 2018. Peptides representing common epitopic sites for AD-associated agents have hMCP-1 activity. #3035. Session Z3. D. Van Alstyne.

23rd International Conference of Alzheimer's Disease International, July 26-29, 2018, Chicago, USA. An Amyloid beta-Derived Peptide Transforms rat glial progenitor cells into microglia. Published in:Alzheimers' and Dementia 14(7):P1529 and doi.1016/j.jalz2018.07.049

Our presentation at the Keystone Symposia attracted the attention of Morgan Sheng, VP Neuroscience, Genentech. We were preparing to initiate "Proof of Concept", preclinical trials in mice. However, the collaboration was cancelled when Morgan left the pharmaceutical industry to return to an academic position at the Broad Institute, Boston.

Septa Therapeutics is now raising the US$350,000 to finance these trials at the Charles River contract research laboratories.

Rat brain stem cells grown in tissue culture (a) before and (b) after exposure to amyloid beta-derived peptide. (click to enlarge)

Rat brain stem cells after exposure to amyloid beta-derived peptide, identified as microglia. (click to enlarge)